San Francisco, California, October 14, 2024 — Cothera Bioscience, a leading biotech innovator advancing clinical stage therapeutics for previously undruggable oncology targets with high unmet medical needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical program PC-002, a...
Cothera Bioscience Announces Orphan Drug Designation for PC-002 for the Treatment of Burkitt Lymphoma
San Francisco December 7, 2023 – Cothera Bioscience, a clinical stage biotech company developing therapeutics for previously undruggable oncology targets with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PC-002, a first-in-class deubiquitinase (DUB) inhibitor that induces myc...
Cothera Announces Dosing of First Patient in Phase 2 Clinical Trial to Test Its DUB Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
San Francisco, December 19, 2022--Cothera Bioscience today announced that it has dosed the first patient with PC-002, a first-in-class deubiquitinase (DUB) inhibitor, in a global multi-center phase 2 clinical trial for the treatment of high-grade B-cell lymphoma with Myc rearrangement (NCT05263583). This is a single-arm, single-agent proof-of-concept trial designed to...
